124 related articles for article (PubMed ID: 16732709)
21. Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
Geriatrics; 2005 Aug; 60(8):12. PubMed ID: 16104078
[No Abstract] [Full Text] [Related]
22. Diabetes: assessing the pipeline.
Lebovitz H
Atheroscler Suppl; 2006 Apr; 7(1):43-9. PubMed ID: 16504599
[TBL] [Abstract][Full Text] [Related]
23. Muraglitazar and the FDA: what constitutes drug safety?
Liebson PR
Prev Cardiol; 2006; 9(2):110-4. PubMed ID: 16603830
[No Abstract] [Full Text] [Related]
24. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
Younk LM; Uhl L; Davis SN
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):753-63. PubMed ID: 21521130
[TBL] [Abstract][Full Text] [Related]
25. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
[TBL] [Abstract][Full Text] [Related]
27. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
Genuth S
Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
[TBL] [Abstract][Full Text] [Related]
28. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Lecka-Czernik B
IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
[TBL] [Abstract][Full Text] [Related]
29. Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus.
Galligan A; Greenaway TM
Intern Med J; 2016 May; 46(5):540-9. PubMed ID: 27170238
[TBL] [Abstract][Full Text] [Related]
30. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?
Rensing KL; Reuwer AQ; Arsenault BJ; von der Thüsen JH; Hoekstra JB; Kastelein JJ; Twickler TB
Diabetes Obes Metab; 2011 Dec; 13(12):1073-87. PubMed ID: 21736687
[TBL] [Abstract][Full Text] [Related]
31. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Heinzl S
Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
[No Abstract] [Full Text] [Related]
32. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
33. [Prospective pioglitazone clinical trial in macrovascular events].
Asanuma H; Kitakaze M
Nihon Rinsho; 2012 May; 70 Suppl 3():301-8. PubMed ID: 22768537
[No Abstract] [Full Text] [Related]
34. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
Mittra S; Sangle G; Tandon R; Sharma S; Roy S; Khanna V; Gupta A; Sattigeri J; Sharma L; Priyadarsiny P; Khattar SK; Bora RS; Saini KS; Bansal VS
Br J Pharmacol; 2007 Feb; 150(4):480-7. PubMed ID: 17211457
[TBL] [Abstract][Full Text] [Related]
35. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
36. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
Panicker GK; Karnad DR; Salvi V; Kothari S
J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
[TBL] [Abstract][Full Text] [Related]
38. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
[TBL] [Abstract][Full Text] [Related]
39. Diabetes and cardiovascular disease: from new mechanisms to new therapies.
Gajos G
Pol Arch Intern Med; 2018 Mar; 128(3):178-186. PubMed ID: 29579035
[TBL] [Abstract][Full Text] [Related]
40. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
Monami M; Dicembrini I; Mannucci E
Acta Diabetol; 2017 Jan; 54(1):19-36. PubMed ID: 27488726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
